Drugs / Verdiperstat
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04616456 | Dec 2020 → Jan 2022 | multiple system atrophy, cerebellar type, multiple system atrophy, parkinsonian type | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT05184569 | Apr 2022 → Jan 2027 expected | semantic dementia | Peter Ljubenkov, MD | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01457807 | Nov → Dec 2011 | Parkinson disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00914303 | Jun 2009 → Mar 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00729443 | Jul → Nov 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT02388295 | Apr 2015 → Sep 2016 | multiple system atrophy | AstraZeneca | Completed | Missed primary |
| Phase 2 | NCT01527695 | Apr → Dec 2012 | Parkinson disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2/32 trials · 2 missed | ||||||
| Phase 2/3 | NCT04436510 | Jul 2020 → Apr 2022 | amyotrophic lateral sclerosis | Merit E. Cudkowicz, MD | Completed | Missed primary |
| Phase 2/3 | NCT04297683 | Jun 2020 → Jul 2027 expected | amyotrophic lateral sclerosis | Merit E. Cudkowicz, MD | Recruiting | Missed primary |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT03952806 | Jul 2019 → Jul 2021 | multiple system atrophy | Biohaven Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase not stated1 trial | ||||||
| — | NCT05086094 | — | multiple system atrophy | Biohaven Pharmaceuticals, Inc. | No longer available | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01603069 Comparator | Oct 2012 → Jun 2013 | Parkinson disease | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Verdiperstat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05184569 ↗ |
| Known as | AZD3241 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00914303 ↗ |
| Known as | BHV-3241 | “The purpose of this study is to compare the efficacy of verdiperstat (BHV-3241) versus placebo in participants with Multiple System Atrophy” NCT03952806 ↗3“Oral Verdiperstat (BHV-3241) in Patients With Semantic Variant Primary Progressive Aphasia (svPPA) Due to TDP-43 Pathology” NCT05184569 ↗ “Verdiperstat (BHV-3241) is currently being used in a phase 3 active drug trial at Massachusetts Hospital.” NCT04616456 ↗ “BHV3241, verdiperstat” NCT05086094 ↗ |
| Known as | BHV-3421 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297594 ↗ |
| Action | Inhibit | “AZD3241 myeloperoxidase (MPO) inhibitor trial” NCT02388295 ↗1“Myeloperoxidase inhibitor” CHEMBL4297594 ↗ |
| Modality | Small molecule | — CHEMBL4297594 ↗ |
| Route | Oral | “single oral dose” NCT00729443 ↗ |
| Target | MPO | “Myeloperoxidase inhibitor” CHEMBL4297594 ↗ |